As Amgen's trio of Horizon drugs disappoints, execs urge analysts to give them more time
2nd May 2025 Uncategorised 0While Amgen’s legacy products are thriving, those gained from the company’s $27.8 billion buyout of Horizon Therapeutics in 2023 are struggling, especially blockbuster eye disease treatment Tepezza, which saw a 17% sequential decline in the first quarter.
More: As Amgen's trio of Horizon drugs disappoints, execs urge analysts to give them more time
Source: fierce